The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Clariant Healthcare highlighted Vitipure Meglumine LEX and VitiPure Superior at the recently concluded CPhI India
10+ emerging markets, Japan & ANZ transition in final phase
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
New facility is part of Aptar Pharma’s global expansion program
Subscribe To Our Newsletter & Stay Updated
